调节性T细胞重编程公司RegCell获得850万美元种子融资，推动其同类首个表观遗传调节性t细胞重编程平台在2025年进行首次人体临床试验-动脉网

Japanese-Founded Regulatory T-cell Reprogramming Company RegCell Secures $45.8M in Funding and Completes U.S. Headquarters Transition

CISION 等信源发布 2025-03-18 19:58



可切换为仅中文







Funding includes

资金包括

$8.5M

850万美元

from an oversubscribed seed financing with up to

来自超额认购的种子融资，最高可达

$37.3M

3730万美元

in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring

来自日本医疗研究开发机构（AMED）的非稀释性投资，凸显了

Japan's

日本的

commitment to breakthrough therapies

致力于突破性疗法

Funding will advance RegCell's first-in-class epigenetic regulatory T-cell reprogramming platform to first-in-human clinical trials in 2025

资金将推动RegCell公司首个表观遗传调节T细胞重编程平台在2025年进入首次人体临床试验。

Strategic move to a U.S.-based entity will accelerate clinical development, global partnerships, and commercialization opportunities for company founded by pioneering immunologist

战略性地转移到一家美国的实体公司将加速由开创性免疫学家创立的公司的临床开发、全球合作和商业化机会。

EMERYVILLE, Calif.

加利福尼亚州埃默里维尔

，

March 18, 2025

2025年3月18日

/PRNewswire/ -- RegCell, Inc., a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T-cells (Tregs), today announced the closing of an oversubscribed seed round and its transition to a U.S.-based company..

/PRNewswire/ -- RegCell, Inc. 是一家利用表观遗传重编程平台开发针对自身免疫疾病和移植的一流疗法的生物技术公司，该平台利用调节性 T 细胞 (Tregs) 的天然生物学特性。该公司今日宣布已完成超额认购的种子轮融资，并转型为一家美国本土公司。

The

$8.5 million

850万美元

seed financing was co-led by The

种子轮融资由The共同领投

University of Tokyo

东京大学

Edge Capital Partners (UTEC) and Fast Track Initiative (FTI), with participation from Celadon Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC), and

Edge Capital Partners（UTEC）和Fast Track Initiative（FTI），参与方包括Celadon Partners、三菱UFJ资本、大阪大学风险投资（OUVC），以及

Kyoto University

京都大学

Innovation Capital (Kyoto i-Cap).

创新资本（京都 i-Cap）。

In addition, RegCell was awarded up to

此外，RegCell 获得了高达

$37.3 million

3730万美元

in non-dilutive funding (¥5.6 Billion) from

非稀释性资金（56亿日元）来自

Japan's

日本的

Agency for Medical Research and Development (AMED). This funding will support the development of RegCell's epigenetic reprogramming platform through clinical proof-of-concept and further validates RegCell's technology and

日本医疗研究开发机构 (AMED)。这笔资金将支持 RegCell 的表观遗传重编程平台通过临床概念验证进行开发，并进一步验证 RegCell 的技术。

Japan's

日本的

commitment to innovation.

致力于创新。

This additional capital will support RegCell's plans to initiate a first-in-human trial in 2025 targeting an antigen-specific autoimmune indication. AMED's support will fund IND-enabling studies, GMP optimization, and establishing clinical proof-of-concept in the US.

这笔额外的资金将支持RegCell计划在2025年启动一项针对特定抗原自身免疫适应症的首次人体试验。AMED的支持将为新药临床试验（IND）所需的研究、GMP优化以及在美国建立临床概念验证提供资金。

RegCell's scientific founder, Professor

RegCell的科学创始人，教授

Shimon Sakaguchi

坂口志文

, whose pioneering research led to the discovery of regulatory T cells (Tregs) and their essential function in maintaining immunological self-tolerance, stated, 'This funding accelerates RegCell's mission of developing potentially curative treatments for autoimmune diseases and transplantation and provides a very efficient path to clinical proof of concept.'.

，他的开创性研究促成了调节性T细胞（Tregs）及其在维持免疫自耐受中的关键功能的发现，他表示：“这笔资金加速了RegCell开发潜在治愈性治疗自身免疫疾病和移植的使命，并为临床概念验证提供了一条非常高效的途径。”

Furthermore, the strategic U.S. corporate restructuring transitions RegCell to a U.S.-based corporation, broadening access to international talent, capital, and partnerships, enhancing R&D capabilities, and expanding business development outreach to global partners. RegCell will continue to operate its core scientific operations to access world-class scientific capabilities in .

此外，美国的战略性企业重组将RegCell转变为一家美国本土公司，拓宽了获取国际人才、资本和合作伙伴的渠道，增强了研发能力，并扩大了与全球伙伴的业务发展范围。RegCell将继续运营其核心科学业务，以获取世界一流的科学能力。

Japan

日本

while leveraging its U.S. footprint to access regulatory and commercialization expertise that tends to be scarce in the emerging Japanese biotech ecosystem.

同时利用其在美国的业务来获取监管和商业化专业知识，这些知识在日本新兴的生物技术生态系统中往往稀缺。

'This funding, combined with our ambitious corporate restructuring, represents a crucial milestone in RegCell's evolution as it propels us forward in our mission to bring groundbreaking immunology therapies to the forefront of global healthcare,' said Dr.

“这笔资金，加上我们雄心勃勃的企业重组，标志着RegCell发展过程中的一个关键里程碑，它推动我们在将开创性的免疫学疗法推向全球医疗前沿的使命中更进一步，”博士表示。

Michael McCullar

迈克尔·麦卡勒

, CEO of RegCell. 'This financial support and U.S.-based restructuring are not just strategic steps; they are forces that will drive both our clinical development and business success in the years ahead.'

RegCell公司首席执行官表示：“这一财务支持和基于美国的重组不仅是战略步骤；它们将是推动我们未来几年临床开发和业务成功的动力。”

On behalf of existing investors, Dr.

代表现有投资者，博士。

Atsushi Usami

臼井厚志

, Partner and Board Director at UTEC and RegCell, shared the following statement 'I am truly delighted that the innovative Treg cell therapy, developed by Prof. Sakaguchi, is progressing towards transformative clinical milestones with the support of

“UTEC和RegCell的合伙人兼董事会董事分享了以下声明：‘我非常高兴，由坂口教授开发的创新Treg细胞疗法在支持下正朝着变革性的临床里程碑迈进。’”

Japan's

日本的

AMED, a team of seasoned drug development experts—primarily from the U.S.—and new investors committed to our shared vision for RegCell. This therapy has the potential to bring relief to countless patients suffering from immune diseases worldwide. I sincerely hope it reaches clinical practice in the most appropriate and widespread manner as soon as possible.'.

AMED，一个由资深药物开发专家（主要来自美国）和新投资者组成的团队，他们致力于我们对RegCell的共同愿景。这种疗法有潜力为全世界无数受免疫疾病困扰的患者带来缓解。我真诚地希望它能尽快以最合适和最广泛的方式应用于临床实践。

Dr.

博士

Koji Yasuda

安田浩二

, Principal at Fast Track Initiative, will join the RegCell Board and added the following statement: 'Regulatory T-cells play a critical role in maintaining immune tolerance, yet translating their biology into effective therapies has been challenging. RegCell's differentiated approach has the potential to address a broad range of autoimmune diseases and beyond.

快速通道计划的负责人将加入RegCell董事会，并补充了以下声明：“调节性T细胞在维持免疫耐受方面发挥着关键作用，但将其生物学特性转化为有效疗法一直具有挑战性。RegCell的独特方法有潜力应对广泛的自身免疫疾病及其他领域。”

We are excited to support this breakthrough Japanese science developed by Prof. Sakaguchi and his team and help bring its impact to the U.S. and global markets.'.

我们很高兴能够支持由坂口教授及其团队开发的这项突破性的日本科学成果，并帮助将其影响带到美国和全球市场。

About RegCell

关于RegCell

RegCell is a global biotechnology company pioneering cell therapies for autoimmune diseases and transplantation. With newly established U.S. headquarters and deep roots in

RegCell是一家全球生物技术公司，率先为自身免疫疾病和移植开发细胞疗法。公司新近设立美国总部，并且深深扎根于

Japan's

日本的

renowned scientific community, RegCell is founded on the pioneering discoveries of Co-Founder Professor

著名的科学界，RegCell 基于联合创始人教授的开创性发现而成立

Shimon Sakaguchi

坂口志文

, a leader in regulatory T-cell (T-reg) biology.

，是调节性T细胞（T-reg）生物学的领导者。

RegCell has developed a proprietary, best-in-class platform to generate stable, epigenetically reprogrammed, antigen-specific Tregs designed to restore immune tolerance. Current autoimmune treatments rely on immunosuppression, leading to persistent adverse events and the need for life-long therapy. RegCell's platform overcomes key barriers that have hindered the development of autoimmune cell therapies by addressing unknown or multiple pathogenic antigens.

RegCell 开发了一个专有的、业内领先的技术平台，用于生成稳定的、表观遗传重编程的、抗原特异性的调节性T细胞（Tregs），旨在恢复免疫耐受。目前的自身免疫疾病治疗方法依赖于免疫抑制，导致持续的不良反应和终身治疗的需求。RegCell 的平台通过应对未知或多种致病抗原，克服了阻碍自身免疫细胞疗法发展的关键障碍。

Unlike genetic modification approaches, RegCell's epigenetic reprogramming technology simplifies manufacturing, enhances safety, and enables scalable production, bringing the promise of transformative cell therapies to a broad spectrum of autoimmune patients, including those with diseases driven by undefined autoantigens..

与基因改造方法不同，RegCell的表观遗传重编程技术简化了生产流程、提高了安全性并实现了可扩展生产，为包括那些由未明确定义的自身抗原驱动疾病的广泛自身免疫疾病患者带来了变革性细胞疗法的希望。

Driven by a vision to redefine self-tolerance, RegCell is committed to delivering safe, life-changing cell therapies that can restore immune tolerance, reverse autoimmune disorders, and overcome challenges in transplantation.

受重新定义自我耐受的愿景驱动，RegCell致力于提供安全、改变生命的细胞疗法，这些疗法可以恢复免疫耐受、逆转自身免疫疾病，并克服移植中的挑战。

For more information, visit

欲了解更多信息，请访问

http://www.regcellbio.com/

About AMED

关于AMED

The Japan Agency for Medical Research and Development (AMED), established in 2015, is a government agency dedicated to accelerating medical innovation and strengthening

2015年成立的日本医疗研究开发机构（AMED）是一个致力于加速医学创新和加强

Japan's

日本的

global competitiveness in healthcare. AMED supports integrated research and development across the medical spectrum, from basic science to clinical applications, to translate cutting-edge discoveries into real-world treatments. As part of this mission, AMED launched the V-ECO (Strengthening Program for Pharmaceutical Startup Ecosystem) grant to foster the growth of .

全球医疗保健竞争力。AMED支持贯穿医学领域的综合研发，从基础科学到临床应用，将前沿发现转化为现实世界的治疗方案。作为这一使命的一部分，AMED启动了V-ECO（制药初创企业生态系统强化计划）拨款，以促进的增长。

Japan's

日本的

biotech sector. This program provides substantial non-dilutive funding to startups developing innovative therapies, contingent upon investment from pre-certified venture capital firms. By supporting early-stage pharmaceutical development, including non-clinical and clinical studies, V-ECO aims to accelerate breakthrough medical innovations and position .

生物技术领域。该计划为开发创新疗法的初创公司提供大量的非稀释性资金，但前提是需要获得预先认证的风险投资公司的投资。通过支持包括非临床和临床研究在内的早期药物开发，V-ECO旨在加速突破性医疗创新并占据有利地位。

Japan

日本

as a leader in biotech entrepreneurship.

作为生物技术创业领域的领导者。

Media Contact:

媒体联系人:

Ignacio Guerrero-Ros

伊格纳西奥·格雷罗-罗斯

, Ph.D.

，博士

Russo Partners LLC